Loading
Iridex Corp Stock: price and insider trades · United States
2 insiders bought €1.2M of shares over the last 90 days, the latest filed 07 Oct 2026.
Iridex Corp: what insiders have been doing
Iridex Corp is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 5 insiders have disclosed 131 filings since 18 October 2025.
Not one open-market sale was filed. On the buying side, 3 insiders reported 121 purchases totalling €1.2M. No amount is published for 4 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 major shareholder, 1 finance chief and 1 senior executive among the declarants. Biggest ticket of the year: €71k, bought by Lin Shih-Yao David and made public on 7 October 2026.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 131 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 177 purchases and no sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 3 January 2026), the company reported revenue of 52.7 m USD and net income of -4.4 m USD.
Within a 30-day window, 79 purchases overlapped with buying by a second insider. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 7 October 2026, 11 days ago.
Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
239
Thresholds
n/a
Buy Volume
€1M
177 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleShih-Yao David Lin90 buys
Romeo R. Dizon69 buys
William M. Moore10 buys
Patrick Mercer2 buys
Beverly A. Huss1 buy
Scott Shuda1 buy
Since the insiders bought
- +29.2%Entry US$0.72 · Close 12 Oct 2026 US$0.93
- +34.0%Entry US$1.00 · Close at T+90 US$1.34
- +19.2%Entry US$0.99 · Close at T+365 US$1.18
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,720 of 24,148 companies
17.2
score / 100
Value10
Quality25
FCF yld-16%
Earn yld-31%
EV/EBITDA·
ROE-73%
Gross mgn37%
Net mgn-8.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.89
Analyst consensus
1 analysts1.00/5
US$2.75Target US$2.75(+209%)US$2.75
Income statement
RevenueUS$52.7M
Gross profitUS$19.2M37% margin
EBITDA-US$1M-2% margin
Net income-US$4.4M-6.9% margin
Valuation
PER (forward)46.5x
Beta0.67
Balance sheet & cash
Market capUS$15.6M
Total debtUS$4.5M
Free Cash Flow-US$2.3M
Debt / Equity110%
Profitability & ownership
ROE-73.1%
ROA-5.9%
% insiders36.7%
% institutions19.5%
Last declaration on 13 October 2026
Declarations239 total
146,313 sharesCommon StockSEC:0002097627-26-000014:0
40,114 shares@ US$1.003.1% of flowCommon StockSEC:0001062993-26-005210:28
Canonical exit: 31 Aug 2025 (T+90)
244 shares@ US$0.930.0% of flowCommon StockSEC:0001062993-26-005214:0
Canonical exit: 3 Mar 2026 (T+90)
10,260 shares@ US$0.940.7% of flowCommon StockSEC:0001062993-26-005214:1
Canonical exit: 5 Mar 2026 (T+90)
20,000 shares@ US$0.941.4% of flowCommon StockSEC:0001062993-26-005214:2
Canonical exit: 9 Mar 2026 (T+90)
18,892 shares@ US$0.9351.3% of flowCommon StockSEC:0001062993-26-005214:3
Canonical exit: 10 Mar 2026 (T+90)
20,000 shares@ US$0.971.4% of flowCommon StockSEC:0001062993-26-005214:4
Canonical exit: 12 Mar 2026 (T+90)
11,404 shares@ US$0.940.8% of flowCommon StockSEC:0001062993-26-005214:5
Canonical exit: 15 Mar 2026 (T+90)
7,675 shares@ US$0.990.6% of flowCommon StockSEC:0001062993-26-005214:6
Canonical exit: 16 Mar 2026 (T+90)
14,202 shares@ US$0.971.0% of flowCommon StockSEC:0001062993-26-005214:7
Canonical exit: 19 Mar 2026 (T+90)
4,031 shares@ US$1.000.3% of flowCommon StockSEC:0001062993-26-005214:8
Canonical exit: 22 Mar 2026 (T+90)
7,009 shares@ US$1.150.6% of flowCommon StockSEC:0001062993-26-005214:9
Canonical exit: 30 Mar 2026 (T+90)
1,330 shares@ US$1.190.1% of flowCommon StockSEC:0001062993-26-005214:10
Canonical exit: 7 Apr 2026 (T+90)
20,000 shares@ US$1.201.8% of flowCommon StockSEC:0001062993-26-005214:11
Canonical exit: 8 Apr 2026 (T+90)
30,000 shares@ US$1.47983.3% of flowCommon StockSEC:0001062993-26-005214:12
Canonical exit: 23 Apr 2026 (T+90)
33,013 shares@ US$1.48473.6% of flowCommon StockSEC:0001062993-26-005214:13
Canonical exit: 27 Apr 2026 (T+90)
4,050 shares@ US$1.480.4% of flowCommon StockSEC:0001062993-26-005214:14
Canonical exit: 30 Apr 2026 (T+90)
637 shares@ US$1.490.1% of flowCommon StockSEC:0001062993-26-005214:15
Canonical exit: 3 May 2026 (T+90)
19,324 shares@ US$1.412.0% of flowCommon StockSEC:0001062993-26-005214:16
Canonical exit: 5 May 2026 (T+90)
40,535 shares@ US$1.44954.4% of flowCommon StockSEC:0001062993-26-005214:17
Canonical exit: 6 May 2026 (T+90)
129 shares@ US$1.460.0% of flowCommon StockSEC:0001062993-26-005214:18
Canonical exit: 10 May 2026 (T+90)
15,703 shares@ US$1.431.7% of flowCommon StockSEC:0001062993-26-005214:19
Canonical exit: 12 May 2026 (T+90)
100 shares@ US$1.380.0% of flowCommon StockSEC:0001062993-26-005214:20
Canonical exit: 13 May 2026 (T+90)
14,943 shares@ US$1.411.6% of flowCommon StockSEC:0001062993-26-005214:21
Canonical exit: 24 May 2026 (T+90)
1,424 shares@ US$1.400.1% of flowCommon StockSEC:0001062993-26-005214:22
Canonical exit: 31 May 2026 (T+90)
25 of 239 declarations
About Iridex Corp
IRIDEX Corporation (ticker: IRIX) is a U.S.-based ophthalmic medical technology company listed on Nasdaq in the United States, part of the NYSE/NASDAQ universe followed by global equity investors. The company was founded in 1989 as IRIS Medical Instruments, Inc., later renamed IRIDEX Corporation in 1996, and has long been associated with Silicon Valley. Its executive offices remain in Mountain View, California, although in February 2026 the company announced plans to relocate its headquarters to San Jose to lower operating costs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm))
IRIDEX focuses on the development, manufacturing, and commercialization of therapeutic laser systems, delivery devices, and single-use consumable instrumentation for ophthalmology. Its core addressable markets are glaucoma and retinal diseases, including diabetic macular edema (DME). Key product families include the Cyclo G6® laser system for glaucoma, the Iridex 532® and Iridex 577® lasers, and the proprietary MicroPulse® technology, which the company positions as a differentiated laser treatment designed to be safer and more tissue-sparing than conventional continuous-wave laser approaches. Consumable probes and delivery accessories are an important part of the product stack and help support recurring revenue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm))
Read moreShow less
From a competitive standpoint, IRIDEX is a niche specialist rather than a broad-line ophthalmic equipment conglomerate. Its investment case rests on clinical differentiation, installed base, and scientific validation, particularly around MicroPulse applications in glaucoma management and retinal therapy. That specialization can be an advantage in targeted indications where surgeons value precision, safety, and repeatability, but it also means the company operates in a competitive, innovation-driven market where reimbursement, adoption rates, and physician preference matter materially. ([iridex.gcs-web.com](https://iridex.gcs-web.com/news-releases/news-release-details/iridex-reports-fourth-quarter-and-full-year-2025-financial?utm_source=openai))
Geographically, the company sells primarily in the United States through a direct sales force, while international business is handled mainly through independent distributors. Its 2025 Form 10-K states that products were sold in the U.S. and Germany directly, and in other international markets via Topcon Corporation and additional distributors, including Italy, the U.K. (glaucoma), India, and smaller markets. The company also stated that its products are sold into more than 100 countries. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm))
Recent company developments have been noteworthy. In March 2026, IRIDEX reported full-year 2025 revenue of $52.7 million versus $48.7 million in 2024, while narrowing net loss to $4.4 million from $8.9 million. In 2025 and early 2026, it highlighted clinical publications supporting MicroPulse, launched a U.K. study in diabetic macular edema, appointed Patrick Mercer as CEO in October 2024, announced a strategic investment in March 2025, and disclosed its headquarters relocation plan in February 2026. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm))
